Form 4: Camp4 Therapeutics CEO Buys Shares
Insider Transaction (Form 4)
Josh Mandel-Brehm, Chief Executive Officer and a Director of Camp4 Therapeutics Corp, purchased 6,551 shares of common stock on August 3, 2026 for $1.65 per share.
Summary
- Open-market purchase: acquired 6,551 Common Stock at $1.65 ($10,809) on August 3, 2026; holds 284,968 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $10,809, committing personal capital to the stock.
Insider Transactions
Josh Mandel-Brehm — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Open-market purchase | Common Stock | 6,551 | $2 | $10.8K | 284,968 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Open-market purchase (6,551 shares) |
Keywords
insider transaction, Form 4, CAMP, Camp4 Therapeutics Corp, bullish, Josh Mandel-Brehm
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.